Related Experiment Video
Updated: Jun 7, 2026
11:13
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
9.1K
Rational design of selective bispecific EPO-R/CD131 agonists
Kailyn E Doiron1,2,3, Jeffrey C Way1,2, Pamela A Silver1,2
1Department of Systems Biology, Harvard Medical School, 210 Longwood Avenue, Boston, MA 02115, USA.
Protein Engineering, Design & Selection : PEDS
|November 9, 2025
Summary
Researchers developed novel bispecific proteins to activate EPO-R/CD131 signaling, offering a new approach for cytokine receptor agonist development and understanding EPO-R/CD131 biology.
Area of Science:
- Biochemistry and Molecular Biology
- Immunology
- Structural Biology
Background:
- Erythropoietin (EPO) signaling is crucial for cell survival, acting via EPO-R/EPO-R or EPO-R/CD131 complexes.
- The precise mechanism and structural basis of EPO signaling through EPO-R/CD131 remain incompletely understood and debated.
Purpose of the Study:
- To construct a structural model of the EPO-R/CD131 complex.
- To design and validate bispecific proteins that selectively activate EPO-R/CD131 signaling.
Main Methods:
- Structural modeling of the EPO-R/CD131 complex.
- Design and engineering of anti-EPO-R and anti-CD131 bispecific proteins (tandem scFv, bispecific antibody formats).
- Assessment of STAT5 phosphorylation as a readout for EPO-R/CD131 activation.
Main Results:
- A structural model of EPO-R/CD131 was developed.
- Engineered bispecific proteins, particularly in tandem scFv and bispecific antibody formats, selectively activated EPO-R/CD131.
- Activation was confirmed by STAT5 phosphorylation, independent of EPO-R/EPO-R engagement.
- Modifications to binding domain arrangement and linker length aligned with the structural model.
Conclusions:
- Bispecific scaffolds are effective tools for developing cytokine receptor agonists.
- The study provides a foundation for further investigation into EPO-R/CD131 biology.
- These findings support the potential for future clinical development of EPO-R/CD131-targeting therapeutics.
